Battered King picks new CFO after months of questions

King Pharmaceuticals appointed Joseph Squicciarino chief financial officer.
News of the former Revlon CFO's appointment buoyed the troubled company's stocks, battered in recent months by a botched merger and questions over past earnings statements. A bid by Mylan Laboratories to acquire King was scuttled in February after the Bristol, Tenn.-based company said it would have to restate earnings results from 2002 through the first half of 2004. Squicciarino, who worked for
Johnson & Johnson and Bristol- Myers Squibb before joining Revlon, succeeds James Lattanzi, whose retirement was announced in April.

You must be a registered member of MMM to post a comment.

Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.